The Drug Regulatory Authority of Pakistan (DRAP) has issued a public health alert after identifying a falsified version of the Hexaxim vaccine, which is administered to infants and young children to protect them against six infectious diseases.
The warning has raised concerns about the availability of unauthorized vaccines in the country, particularly those intended for children. Parents, healthcare professionals, hospitals and medical stores have been urged to remain cautious when purchasing or administering the vaccine.
According to DRAP, Hoechst Pakistan Limited, the local distributor of French pharmaceutical company Sanofi, reported the circulation of a suspicious Hexaxim vaccine carrying batch number X3H421VA.
The company informed the regulatory authority that the vaccine was being presented in vial form, which is not registered or authorized for import into Pakistan.
DRAP has highlighted the issue to prevent the use and distribution of potentially falsified vaccine products.
DRAP Identifies Unauthorized Hexaxim Vaccine Batch
According to the regulatory alert, the suspicious product carries batch number X3H421VA and is being marketed in a vial presentation.
However, this particular presentation has not been approved for registration or import into Pakistan.
The identification of an unauthorized vaccine is a serious concern because falsified medical products may not meet the required standards of quality, safety and effectiveness.
Parents and healthcare providers are therefore advised to pay close attention to the product’s packaging, batch information and authorized supply channels before using any Hexaxim vaccine.
The alert follows a report submitted by Hoechst Pakistan Limited, which brought the suspicious product to the attention of the regulatory authority.
What Is the Hexaxim Vaccine Used For?
Hexaxim is a combination vaccine designed to protect infants and young children against six serious infectious diseases.
These include diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and infections caused by Haemophilus influenzae type b (Hib).
Vaccination plays an important role in protecting children from diseases that can cause serious complications, long-term health problems and, in some cases, death.
Combination vaccines also help simplify childhood immunisation by providing protection against multiple diseases through a single vaccination.
This makes the availability of genuine and properly authorized vaccines particularly important for parents and healthcare providers.
What Should Parents and Healthcare Providers Do?
Following DRAP’s warning, parents should avoid purchasing vaccines from unverified sellers or unauthorized sources.
Healthcare professionals, hospitals, pharmacies and medical distributors should carefully check the product’s presentation and batch number before accepting or administering Hexaxim.
Anyone who comes across a product carrying the suspicious batch number X3H421VA in the unauthorized vial presentation should avoid using it and seek guidance from the relevant regulatory authorities.
Parents who have concerns about a vaccine already administered to their child should contact their healthcare provider for appropriate advice.
Why DRAP’s Alert Matters for Child Vaccination
The circulation of falsified vaccines can create serious public health risks, particularly when products are intended for infants and young children.
Using an unauthorized or counterfeit vaccine may expose children to products whose quality, safety and effectiveness have not been properly established.
DRAP’s alert highlights the importance of monitoring pharmaceutical supply chains and ensuring that medicines and vaccines available in Pakistan meet regulatory requirements.
Parents are encouraged to remain informed about official health warnings while continuing their children’s routine immunisation according to medical advice.
Ensuring access to genuine vaccines remains essential for protecting children against preventable infectious diseases.



